Atricure Inc. Stock
Price
Target price
?
?
0.000%
-
0.000%
€43.22
08:04 / Frankfurt
WKN: A0ES9W / Symbol: ATRC / Name: AtriCure / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Atricure Inc. Stock
There is no change in the price for Atricure Inc. today.
Atricure Inc. is currently one of the favorites of our community with 8 Buy predictions and no Sell predictions.
With a target price of 43 € there is a hugely positive potential of 86.96% for Atricure Inc. compared to the current price of 23.0 €.
Pros and Cons of Atricure Inc. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
S********** s********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | 0.000% | -5.738% | -6.504% | -62.903% | -32.353% | -62.903% | -60.000% |
| SI-BONE Inc | 0.000% | -4.878% | 6.364% | -1.681% | -30.769% | - | - |
| Lantheus Holdings Inc | 0.000% | -0.855% | 5.647% | -21.903% | 21.678% | -14.873% | - |
| Lemaitre Vascular Inc | 0.510% | -2.500% | 0.515% | 28.289% | 38.298% | - | - |
Comments
AtriCure (ATRC) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Freedom Capital to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (NASDAQ:ATRC) was given a new $55.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
News
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
This medical device innovator for cardiac surgery reported an insider sale amid a year of negative total returns.
Doraiswamy Vinayak, Chief Scientific Officer of AtriCure (NASDAQ:ATRC), reported the
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?
Sven Wehrwein, a member of the Board of Directors at AtriCure (NASDAQ:ATRC), exercised 10,000 non-qualified stock options and immediately sold the underlying shares in derivative transactions on